跳转至内容
Merck
CN

主要文件

查看所有文档

N7261

去甲替林 盐酸盐

≥98% (HPLC), norepinephrine and serotonin inhibitor, powder

别名:

3-（10,11-二氢-5 H -二苯并[ a , d ] 环庚烯-5-亚基）- N -甲基-1-丙胺 盐酸盐, 去甲阿米替林 盐酸盐

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:
C19H21N · HCl
化学文摘社编号:
894-71-3
分子量:
299.84
NACRES:
NA.77
PubChem Substance ID:
24278107
UNSPSC Code:
41116107
EC Number:
212-973-0
MDL number:
MFCD00058024
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
200
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

去甲替林 盐酸盐, ≥98% (HPLC), powder

Quality Level

200

assay

≥98% (HPLC)

form

powder

color

white to off-white

solubility

ethanol: 100 mg/mL, H2O: soluble

originator

Eli Lilly

SMILES string

Cl.CNCC\C=C1\c2ccccc2CCc3ccccc13

InChI

1S/C19H21N.ClH/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19;/h2-5,7-11,20H,6,12-14H2,1H3;1H

InChI key

SHAYBENGXDALFF-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356), HTR2B(3357), HTR2C(3358), SLC6A2(6530), SLC6A4(6532)

Biochem/physiol Actions

与 5-羟色胺转运体 (K i = 161 nM) 相比，三环类抗抑郁药是去甲肾上腺素转运体 (K i = 3.4 nM) 的一种更强效的抑制剂。5-HT 2 5-羟色胺受体拮抗剂。

Features and Benefits

该化合物收录于 受体分类和信号转导手册的《生物胺转运体 》页面。想要浏览手册的其他页面， 请单击此处。
该化合物由Eli Lilly开发。要浏览其他药物开发化合物和批准的药物/候选药物列表，单击此处。

Still not finding the right product?

Explore all of our products under 去甲替林 盐酸盐

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Faceshields, Gloves

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
BCCG7796
BCCG2928
BCBT1140
BCBN0630V
BCBN0630

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Lindsay F Stead et al.
The Cochrane database of systematic reviews, 12, CD009670-CD009670 (2012-12-14)
Effective pharmacotherapies are available to help people who are trying to stop smoking, but quitting can still be difficult and providing higher levels of behavioural support may increase success rates further. To evaluate the effect of increasing the intensity of
SSRIs: a premature burial.
K Jensen
Clinical pharmacology and therapeutics, 93(3), 234-235 (2012-12-20)
Abdennasser Bardai et al.
European heart journal, 34(20), 1506-1516 (2013-02-22)
Non-cardiac drugs that impair cardiac repolarization (electrocardiographic QT prolongation) are associated with an increased sudden cardiac arrest (SCA) risk. Emerging evidence suggests that non-cardiac drugs that impair cardiac depolarization and excitability (electrocardiographic QRS prolongation) also increase the risk for SCA.
查看所有相关文献

全球贸易项目编号

货号GTIN
N7261-10G04061834117940